ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome
Science Translational Medicine · 18.09.2024 · 16 (765)
DOI: 10.1126/scitranslmed.ado7189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 18.09.2024. Verfasst von Roeland Vanhauwaert und 16 weiteren Autor:innen. Beteiligte Einrichtung: argenx, 9052 Zwijnaarde, Belgium. Hauptthemen laut MEDLINE: Receptor Protein-Tyrosine Kinases, Myasthenic Syndromes, Congenital, Disease Models, Animal, Receptors, Cholinergic. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Muscle-specific kinase (MuSK) is essential for the formation, function, and preservation of neuromuscular synapses. Activation of MuSK by a MuSK agonist antibody may stabilize or improve the function of the neuromuscular junction (NMJ) in patients with disorders of the NMJ, such as congenital myasthenia (CM). Here, we generated and characterized ARGX-119, a first-in-class humanized agonist monoclonal antibody specific for MuSK, that is being developed for treatment of patients with neuromuscular diseases. We performed in vitro ligand-binding assays to show that ARGX-119 binds with high affinity to the Frizzled-like domain of human, nonhuman primate, rat, and mouse MuSK, without off-target binding, making it suitable for clinical development. Within the Fc region, ARGX-119 harbors L234A and L235A mutations to diminish potential immune-activating effector functions. Its mode of action is to activate MuSK, without interfering with its natural ligand neural Agrin, and cluster acetylcholine receptors in a dose-dependent manner, thereby stabilizing neuromuscular function. In a mouse model of DOK7 CM, ARGX-119 prevented early postnatal lethality and reversed disease relapse in adult Dok7 CM mice by restoring neuromuscular function and reducing muscle weakness and fatigability in a dose-dependent manner. Pharmacokinetic studies in nonhuman primates, rats, and mice revealed a nonlinear PK behavior of ARGX-119, indicative of target-mediated drug disposition and in vivo target engagement. On the basis of this proof-of-concept study, ARGX-119 has the potential to alleviate neuromuscular diseases hallmarked by impaired neuromuscular synaptic function, warranting further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- argenx, 9052 Zwijnaarde, Belgium.
- Helen L. and Martin S. Kimmel Center for Biology and Medicine at Skirball Institute of Biomolecular Medicine, NYU School of Medicine, New York, NY 10016, USA.
- Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, Netherlands.
- Department of Neurology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.
- Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY 10016, USA.
- Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA.
ORCID-Profile: Roeland Vanhauwaert, Christophe Steyaert, Stine Marie Jensen, Dana L E Vergoossen, Christa Kneip, Leah Santana, Jaap J Plomp, Roy Augustinus, Shohei Koide, Christophe Blanchetot, Maartje G Huijbers, Steven J Burden
Zitieren
APA
Vanhauwaert, R., Oury, J., Vankerckhoven, B., Steyaert, C., Jensen, S. M., Vergoossen, D. L. E., Kneip, C., Santana, L., Lim, J. L., Plomp, J. J., Augustinus, R., Koide, S., Blanchetot, C., Ulrichts, P., Huijbers, M. G., Silence, K., & Burden, S. J. (2024). ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome. Science Translational Medicine, 16(765). https://doi.org/10.1126/scitranslmed.ado7189
Vancouver
Vanhauwaert R, Oury J, Vankerckhoven B, Steyaert C, Jensen SM, Vergoossen DLE, et al. ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome. Science Translational Medicine. 2024;16(765). doi:10.1126/scitranslmed.ado7189
BibTeX
@article{Vanhauwaert2024,
author = {Vanhauwaert, Roeland and Oury, Julien and Vankerckhoven, Bernhardt and Steyaert, Christophe and Jensen, Stine Marie and Vergoossen, Dana L E and Kneip, Christa and Santana, Leah and Lim, Jamie L and Plomp, Jaap J and Augustinus, Roy and Koide, Shohei and Blanchetot, Christophe and Ulrichts, Peter and Huijbers, Maartje G and Silence, Karen and Burden, Steven J},
title = {ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome},
journal = {Science Translational Medicine},
year = {2024},
volume = {16},
number = {765},
doi = {10.1126/scitranslmed.ado7189}
}
EUVIMED